As of 2026-09-14, the EV/EBITDA ratio of Kala Pharmaceuticals Inc (KALA) is -0.57. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KALA's latest enterprise value is 24.35 mil USD. KALA's TTM EBITDA according to its financial statements is -42.64 mil USD. Dividing these 2 quantities gives us the above KALA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-09-04 | -0.53 |
| 2026-09-03 | -0.56 |
| 2026-09-02 | -0.54 |
| 2026-09-01 | -0.54 |
| 2026-08-31 | -0.64 |
| 2026-08-28 | -0.65 |
| 2026-08-27 | -0.74 |
| 2026-08-26 | -0.74 |
| 2026-08-25 | -0.74 |
| 2026-08-24 | -0.73 |
| 2026-08-21 | -0.74 |
| 2026-08-20 | -0.76 |
| 2026-08-19 | -0.80 |
| 2026-08-18 | -0.80 |
| 2026-08-17 | -0.81 |
| 2026-08-14 | -0.83 |
| 2026-08-13 | -0.82 |
| 2026-08-12 | -0.79 |
| 2026-08-11 | -0.76 |
| 2026-08-10 | -0.70 |
| 2026-08-07 | -0.69 |
| 2026-08-06 | -0.69 |
| 2026-08-05 | -0.66 |
| 2026-08-04 | -0.69 |
| 2026-08-03 | -0.72 |
| 2026-07-31 | -0.70 |
| 2026-07-30 | -0.68 |
| 2026-07-29 | -0.64 |
| 2026-07-28 | -0.63 |
| 2026-07-27 | -0.64 |
| 2026-07-24 | -0.61 |
| 2026-07-23 | -0.60 |
| 2026-07-22 | -0.69 |
| 2026-07-21 | -0.68 |
| 2026-07-20 | -0.69 |
| 2026-07-17 | -0.71 |
| 2026-07-16 | -0.76 |
| 2026-07-15 | -0.89 |
| 2026-07-14 | -0.84 |
| 2026-07-13 | -0.93 |
| 2026-07-10 | -0.99 |
| 2026-07-09 | -1.11 |
| 2026-07-08 | -1.14 |
| 2026-07-07 | -1.23 |
| 2026-07-06 | -1.25 |
| 2026-07-02 | -1.34 |
| 2026-07-01 | -1.41 |
| 2026-06-30 | -1.38 |
| 2026-06-29 | -1.63 |
| 2026-06-26 | -1.93 |